Combination treatment for advanced lung cancer with EGFR mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (MCLA-129 and befotertinib) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if the combination can shrink tumors or slow their growth, especially after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer that cannot be removed by surgery or treated with radiation, and it must have an EGFR exon 19 deletion or L858R mutation.
- Depending on the study part, you may need to have had previous treatments (like EGFR inhibitors) that no longer work, or you may have had no prior treatment for advanced disease.
- You need to be in generally good health, with adequate blood counts, liver and kidney function, and be able to care for yourself (ECOG score 0 or 1).
- You cannot have certain other medical conditions like active hepatitis B or C, HIV, or significant heart problems. Also, you must not have had more than three lines of prior systemic therapy (for some parts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, MCLA-129, for people with advanced non-small cell lung cancer that has specific gene changes (EGFR and MET) and has stopped responding to standard treatments. The drug targets these changes to possibly slow or shrink the cancer.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
This study tests a new targeted pill (befotertinib) combined with chemotherapy for people with advanced EGFR-mutated non-small cell lung cancer. The treatment is adjusted based on how well the cancer responds, using a special blood test (MRD) to guide decisions.
This trial tests a combination of a targeted pill (befotertinib) and radiation for people with stage IV non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The study uses a blood test to guide treatment and aims to see if this combination can help control the cancer better.
Hear when a new Non-Small Cell Lung Cancer、EGFR Sensitive Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.